Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ATOS
ATOS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ATOS News
Atossa Therapeutics Reports FY Losses
5d ago
seekingalpha
ATOS Shares Decline Post-Market Following Earnings Disappointment — CEO Focuses on Innovative Applications for Experimental Cancer Treatment
5d ago
stocktwits
Atossa Therapeutics Reports 2025 Financial Results and Updates
5d ago
PRnewswire
Atossa Therapeutics Reports 2025 Financial Results and Corporate Developments
5d ago
Newsfilter
ATOSSA THERAPEUTICS ANNOUNCES 2025 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS ALONG WITH A CORPORATE UPDATE
5d ago
moomoo
Biotech Investment Revives as Institutional Capital Flows Back
Mar 19 2026
Globenewswire
Atossa Appoints New Medical Directors to Enhance R&D Efforts
Mar 19 2026
Newsfilter
Atossa Therapeutics Provides Strategic Update on Clinical Progress and Future Directions
Feb 11 2026
PRnewswire
Atossa Therapeutics Provides Update on Clinical Progress and FDA Feedback
Feb 11 2026
Newsfilter
Atossa Receives Rare Pediatric Disease Designation for (Z)-endoxifen
Feb 05 2026
PRnewswire
Atossa Therapeutics CEO Steven Quay Named One of Top 50 Healthcare Technology CEOs of 2025
Jan 21 2026
PRnewswire
Atossa Therapeutics CEO Steven Quay Recognized as Top 50 Healthcare Technology CEO of 2025
Jan 21 2026
Newsfilter
Atossa Therapeutics Receives FDA Orphan Drug Designation, Stock Rises Nearly 13%
Jan 20 2026
NASDAQ.COM
Atossa Therapeutics (ATOS) Receives FDA Orphan Drug Designation, Stock Rises 12.98%
Jan 17 2026
NASDAQ.COM
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen in Duchenne Muscular Dystrophy
Jan 16 2026
Newsfilter
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen in Duchenne Muscular Dystrophy
Jan 16 2026
PRnewswire
Show More News
